Susquehanna Fundamental Investments, LLC Mirati Therapeutics, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $1.06 Million - $1.52 Million	-8,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $739,928 - $993,719	5,600 Added 233.33%	8,000 $1.42 Million
Q2 2021 Aug 11, 2021	SELL	$144.0 - $179.73 $244,800 - $305,541	-1,700 Reduced 41.46%	2,400 $388,000
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $254,271 - $354,576	1,600 Added 64.0%	4,100 $702,000
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $22,652 - $33,454	200 Added 8.7%	2,500 $415,000
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $165,623 - $276,897	2,300 New	2,300 $263,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.